Approval · Notice of Compliance 36044 · 2025
NAROPIN: Notice of Compliance 36044
Issued September 22, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36044
- Date
- September 22, 2025
- Company
- Aspen Pharmacare Canada Inc.Oakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Update to package labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAROPIN | Not yet assigned | — |
Medicinal ingredients
- ROPIVACAINE HYDROCHLORIDE 2 MG per ML
- ROPIVACAINE HYDROCHLORIDE 5 MG per ML
- ROPIVACAINE HYDROCHLORIDE 10 MG per ML